George Golumbeski insider trades: Sage Therapeutics (SAGE) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where George reports to the SEC
Open-market buys and sales
5 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| May 5, 2022 | SAGE | ↑ Buy | 8,000 | $31.45 | $252K | Direct | May 9, 2022 (4d) |
| Apr 26, 2022 | STTK | ↑ Buy | 28,330 | $3.63 | $103K | Direct | Apr 27, 2022 (1d) |
| Apr 22, 2022 | STTK | ↑ Buy | 26,283 | $3.69 | $97K | Direct | Apr 26, 2022 (4d) |
| Mar 4, 2019 | ENTA | ↓ Sell | 9,280 | $103.65 | $962K | Direct | Mar 6, 2019 (2d) |
| Feb 12, 2019 | ENTA | ↓ Sell | 13,500 | $90.06 | $1.2M | Direct | Feb 13, 2019 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About George Golumbeski's insider trades
George Golumbeski is an insider at Sage Therapeutics (SAGE). Since Feb 12, 2019, George has reported 3 open-market purchases worth $451K and 2 sales worth $2.2M on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (32 filings), shares returned to the company (2 filings), option exercises (2 filings), other transactions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every SAGE insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.